CoChat

Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression

Open access

The DOI matches its Crossref record; 38 of the 41 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The global surge in the omicron (B.1.1.529) variant has resulted in many individuals with hybrid immunity (immunity developed through a combination of SARS-CoV-2 infection and vaccination). We aimed to systematically review the magnitude and duration of the protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against infection and severe disease caused by the omicron variant. METHODS: For this systematic review and meta-regression, we searched for cohort, cross-sectional, and case-control studies in MEDLINE, Embase, Web of Science, ClinicalTrials.gov, the Cochrane Central Register of Controlled Trials, the WHO COVID-19 database, and Europe PubMed Central from Jan 1, 2020, to June 1, 2022, using keywords related to SARS-CoV-2, reinfection, protective effectiveness, previous infection, presence of antibodies, and hybrid immunity. The main outcomes were the protective effectiveness against reinfection and against hospital admission or severe disease of hybrid immunity, hybrid immunity relative to previous infection alone, hybrid immunity relative to previous vaccination alone, and hybrid immunity relative to hybrid immunity with fewer vaccine doses. Risk of bias was assessed with the Risk of Bias In Non-Randomized Studies of Interventions Tool. We used log-odds random-effects meta-regression to estimate the magnitude of protection at 1-month intervals. This study was registered with PROSPERO (CRD42022318605). FINDINGS: 11 studies reporting the protective effectiveness of previous SARS-CoV-2 infection and 15 studies reporting the protective effectiveness of hybrid immunity were included. For previous infection, there were 97 estimates (27 with a moderate risk of bias and 70 with a serious risk of bias). The effectiveness of previous infection against hospital admission or severe disease was 74·6% (95% CI 63·1-83·5) at 12 months. The effectiveness of previous infection against reinfection waned to 24·7% (95% CI 16·4-35·5) at 12 months. For hybrid immunity, there were 153 estimates (78 with a moderate risk of bias and 75 with a serious risk of bias). The effectiveness of hybrid immunity against hospital admission or severe disease was 97·4% (95% CI 91·4-99·2) at 12 months with primary series vaccination and 95·3% (81·9-98·9) at 6 months with the first booster vaccination after the most recent infection or vaccination. Against reinfection, the effectiveness of hybrid immunity following primary series vaccination waned to 41·8% (95% CI 31·5-52·8) at 12 months, while the effectiveness of hybrid immunity following first booster vaccination waned to 46·5% (36·0-57·3) at 6 months. INTERPRETATION: All estimates of protection waned within months against reinfection but remained high and sustained for hospital admission or severe disease. Individuals with hybrid immunity had the highest magnitude and durability of protection, and as a result might be able to extend the period before booster vaccinations are needed compared to individuals who have never been infected. FUNDING: WHO COVID-19 Solidarity Response Fund and the Coalition for Epidemic Preparedness Innovations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(22)00801-5

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study selection *There were two rounds of full-text screening. Studies not meeting general inclusion criteria were excluded in the first round. In the second round, articles were screened with criteria specific to the types of exposures and comparators being reported (ie, previous infection and hybrid immunity). †There were 16 unique articles: nine articles reported on one study, five articles reported on two studies (one on previous infection and one on hybrid immunity), one article reported on three studies (one on previous infection and two on hybrid immunity), and one article reported on four studies (two on previous infection and two on hybrid immunity). Seven articles reported data for previous infection and hybrid immunity.
Figure 1 Study selection *There were two rounds of full-text screening. Studies not meeting general inclusion criteria were excluded in the first round. In the second round, articles were screened with criteria specific to the types of exposures and comparators being reported (ie, previous infection and hybrid immunity). †There were 16 unique articles: nine articles reported on one study, five articles reported on two studies (one on previous infection and one on hybrid immunity), one article reported on three studies (one on previous infection and two on hybrid immunity), and one article reported on four studies (two on previous infection and two on hybrid immunity). Seven articles reported data for previous infection and hybrid immunity.CC BY · PubMed Central
Figure 2 Protection against omicron variant conferred by previous infection or hybrid immunity compared to immune-naive individuals over time This analysis uses a log-odds meta-regression model. Points of the same color represent estimates from the same study. The diameter of the circles varies with the sample size of the study. Dotted lines represent 95% CIs. Solid black lines represent point estimates.
Figure 2 Protection against omicron variant conferred by previous infection or hybrid immunity compared to immune-naive individuals over time This analysis uses a log-odds meta-regression model. Points of the same color represent estimates from the same study. The diameter of the circles varies with the sample size of the study. Dotted lines represent 95% CIs. Solid black lines represent point estimates.CC BY · PubMed Central
Figure 3 Protection against omicron variant conferred by the primary series vaccine, first booster vaccine, previous infection, and hybrid immunity compared to immune-naive individuals over time The shaded areas denote 95% CIs. Vaccine effectiveness data were procured from a separate systematic review.
Figure 3 Protection against omicron variant conferred by the primary series vaccine, first booster vaccine, previous infection, and hybrid immunity compared to immune-naive individuals over time The shaded areas denote 95% CIs. Vaccine effectiveness data were procured from a separate systematic review.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 667

Metadata

Authors
Bobrovitz, N., Ware, H., Ma, X., Li, Z., Hosseini, R., Cao, C., Selemon, A., Whelan, M., Premji, Z., Issa, H., Cheng, B., Abu Raddad, L. J., Buckeridge, D. L., Van Kerkhove, M. D., Piechotta, V., Higdon, M. M., Wilder-Smith, A., Bergeri, I., Feikin, D. R., Arora, R. K., Patel, M. K., & Subissi, L.
Affiliations
  • University of Calgary (CA)
  • University of Toronto (CA)
  • University of British Columbia (CA)
  • University of Victoria (CA)
  • University College London (GB)
  • McGill University (CA)
  • Robert Koch Institute (DE)
  • Johns Hopkins University (US)
  • World Health Organization (CH)
Corresponding author
Bobrovitz, Niklas
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2023-05
Volume
23
Issue
5
Pages
556-567
ISSN
1473-3099 (ISSN-L)
OpenAlex
W4317356311
Cited by
614
References
41
Citations by year
2026: 68 · 2025: 131 · 2024: 227 · 2023: 187
FWCI
29.00
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Infectious Diseases (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Publication server of the Robert Koch Institute (Robert Kock Institute) (acceptedVersion, cc-by)
  • Publication server of the Robert Koch Institute (Robert Kock Institute) (submittedVersion, cc-by)
  • UVic’s Research and Learning Repository (University of Victoria) (submittedVersion)
Funders
  • World Health Organization
  • Coalition for Epidemic Preparedness Innovations
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords
SARS-CoV-2, Omicron variant, hybrid immunity, prior SARS-CoV-2 infection, reinfection, protective effectiveness, severe COVID-19, hospitalization, waning immunity, COVID-19 vaccination, antibody response, duration of protection, risk of bias, risk of bias in non-randomized studies
MeSH terms
Reinfection, COVID-19, SARS-CoV-2, Cross-Sectional Studies, Humans, Adaptive Immunity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. https://app.cochat.ai/papers/10.1016/s1473-3099(22)00801-5
The paper
Bobrovitz, N., Ware, H., Ma, X., Li, Z., Hosseini, R., Cao, C., Selemon, A., Whelan, M., Premji, Z., Issa, H., Cheng, B., Abu Raddad, L. J., Buckeridge, D. L., Van Kerkhove, M. D., Piechotta, V., Higdon, M. M., Wilder-Smith, A., Bergeri, I., Feikin, D. R., . . . Subissi, L. (2023). Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(22)00801-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.